Regarding the efficacy of downstream target inhibition, e.g. CCNE2 inhibitors, to overcome imatinib resistance, further studies are necessary to address the role of KMT2D in therapy resistant CML. The gene discussed is CCNE2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.